100% satisfaction guarantee Immediately available after payment Both online and in PDF No strings attached
logo-home
NR 603 Week 2 Part 1 and 2 B. Ingram £4.99   Add to cart

Exam (elaborations)

NR 603 Week 2 Part 1 and 2 B. Ingram

 1 view  0 purchase

NR 603 Week 2 Part 1 and 2 B. Ingram

Preview 2 out of 8  pages

  • September 6, 2022
  • 8
  • 2022/2023
  • Exam (elaborations)
  • Questions & answers
All documents for this subject (2)
avatar-seller
biriamoraa07
Week 2: Case Discussion Pulmonary – Part 1

1. What is your primary diagnosis for Michelle given the pattern of occurrence of symptoms, exam
results, and recent history? Include the rationale and a reference for your diagnoses.

 Diagnosis: Mild to moderate persistent asthma with episodes of shortness of breath (SOB).
 ICD code: J45.30 Asthma

The Global Initiative for Asthma (GINA) 2020 defines asthma as a chronic airway inflammation
characterized by respiratory symptoms such as SOB, cough, wheezing and tightness of the chest, along
with a variable expiratory airflow limitation. A diagnosis can be confirmed by asking about recent
respiratory symptoms and by performing a pulmonary function test (PFT). A diagnosis of asthma can be
diagnosed with the patients’ respiratory symptoms and a FEV1 greater than 12% difference between a
pre-and-post bronchodilator PFT (GINA, 2020).

Rationale: Considering the patients history of seasonal allergies, a recent visit to an urgent care with
complaints of SOB and now the assessment of the PFT results in the office can assist in the diagnosis.
The patient’s physical exam presents slight wheezing on inspiration and forced expiration with
wheezing that does not clear with forceful coughing. The patients pre-PFT resulted in a FEV1/FVC of
60% and the post PFT resulted in a FEV1/FVC of 75%, which is greater than a 12% improvement
indicating a diagnosis of asthma as per the GOLD guidelines (GINA, 2020).


2. What is your first-line treatment plan for Michelle including medications, labs, education, referrals,
and follow-up? Identify the drug class of each medication you prescribe and exactly what symptom
it is targeted to address.


Medications:
GINA (2020) no longer recommends only starting with a SABA only treatment but a SABA and an ICS
containing controller treatment. So, the initial therapy for Michelle would include a daily low dose ICS
and SABA.
 Inhaled corticosteroid- Fluticasone propionate 88 mcg, IH 1 puff daily. Fluticasone is an
inhaled corticosteroid that suppresses inflammation, reduces airway hyperresponsiveness
and controls asthma symptoms like shortness of breath.
 SABA- Albuterol sulfate: PROAIR HFA 108 mcg/puff Sig: 2 puff PO Q4-6 hours as needed for
SOB. Albuterol is a Short acting beta 2 agonist that rapidly relaxes the muscle lining of the
airways thereby allowing an increase in airflow and decreasing shortness of breath and
cough.

Labs:
 No labs are needed at this time. (GINA, 2020).

Education:
 Create an asthma action plan and educate the patient on the steps required if symptoms
worsen or when to seek emergency care. The patient will be given a copy (GINA, 2020).
This study source was downloaded by 100000838234991 from CourseHero.com on 09-06-2022 08:14:39 GMT -05:00


https://www.coursehero.com/file/123213914/NR-603-Week-2-Part-1-and-2-B-Ingramdocx/

,  Michelle should be educated on the use of the prescribed medications and how to
administer them to herself.
 Viral infections, allergens at home or work, tobacco smoke, exercise, and stress can
exacerbate symptoms. Follow the asthma action plan when symptoms worsen. If unrelieved
by action plan, go to the nearest emergency room for treatment.


Referrals:
Michelle does not currently need a referral currently. If her symptoms do not improve, worsen, or
she experiences an increase in symptoms, then a referral should be considered.

Follow up:
Michelle should follow up in 2 weeks to evaluate the effectives of the newly prescribed medications
and any possible side effects she may be experiencing.
She should then follow up in 3 months to assess and monitor her asthma symptoms and assess if a
step up in therapy in warranted or even a step down (NIH, 2021).

3. Address Michelle's request for an antibiotic.
Normansell et. al, 2018 explains that although antibiotics are sometimes included in the treatment is
acute asthma exacerbations, antibiotics are only prescribed when clear signs, symptoms, or laboratory test
results are suggestive of bacterial infections. These symptoms include persistent daily symptoms greater than
14 days, fever, shortness of breath, and ineffective medication management.
Reference:
Asthma Care Diagnosing and Managing Asthma (2021). National Institutes of Health. Retrieved from:
https://www.nhlbi.nih.gov/files/docs/guidelines/asthma_qrg.pdf
Global Initiative for Asthma (GINA). (2020). Global Strategy for Asthma Management and Prevention. Retrieved
from: https://ginasthma.org/wpcontent/uploads/2020/06/GINA-2020-report_20_06_04-1-wms.pdf
Normansell, R., Sayer, B., Waterson, S., Dennett, E. J., Del Forno, M., & Dunleavy, A. (2018). Antibiotics for
exacerbations of asthma. The Cochrane database of systematic reviews, 6(6), CD002741.
https://doi.org/10.1002/14651858.CD002741.pub2


Week 2: Case Discussion Pulmonary – Part 2

1. Determine appropriate treatment plan for Michelle. Discuss medications, doses, Durable Medical
Equipment, and any testing, and apply these directly to her case. Provide your rationale with
evidence.

Treatment plan: Testing- According to the Infectious Diseases Society of America (2018) there
are multiple options for diagnostic testing of influenza however, the ideal diagnostic test should
produce rapid, accurate results with high sensitivity and high specificity to detect the influenza viruses
in respiratory specimens at reasonable cost. Michelle has tested positive for Influenza A in the office
and because she has a history of Asthma, treatment should begin as soon as possible. A
nasopharyngeal swab is a rapid testing method often used in outpatient settings to confirm the
This study source was downloaded by 100000838234991 from CourseHero.com on 09-06-2022 08:14:39 GMT -05:00


https://www.coursehero.com/file/123213914/NR-603-Week-2-Part-1-and-2-B-Ingramdocx/

The benefits of buying summaries with Stuvia:

Guaranteed quality through customer reviews

Guaranteed quality through customer reviews

Stuvia customers have reviewed more than 700,000 summaries. This how you know that you are buying the best documents.

Quick and easy check-out

Quick and easy check-out

You can quickly pay through credit card for the summaries. There is no membership needed.

Focus on what matters

Focus on what matters

Your fellow students write the study notes themselves, which is why the documents are always reliable and up-to-date. This ensures you quickly get to the core!

Frequently asked questions

What do I get when I buy this document?

You get a PDF, available immediately after your purchase. The purchased document is accessible anytime, anywhere and indefinitely through your profile.

Satisfaction guarantee: how does it work?

Our satisfaction guarantee ensures that you always find a study document that suits you well. You fill out a form, and our customer service team takes care of the rest.

Who am I buying these notes from?

Stuvia is a marketplace, so you are not buying this document from us, but from seller biriamoraa07. Stuvia facilitates payment to the seller.

Will I be stuck with a subscription?

No, you only buy these notes for £4.99. You're not tied to anything after your purchase.

Can Stuvia be trusted?

4.6 stars on Google & Trustpilot (+1000 reviews)

83100 documents were sold in the last 30 days

Founded in 2010, the go-to place to buy revision notes and other study material for 14 years now

Start selling
£4.99
  • (0)
  Add to cart